Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that MSI-H status confers therapeutic sensitivity to Ipilimumab, Nivolumab in patients with Colorectal Adenocarcinoma.
The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.
This statement is based on a regulatory approval from the European Medicines Agency:
YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.